Components

SimulFluor^® Respiratory Screen - (Catalog No. 5296).Respiratory Control Slides - (Catalog No. 5071)PBS - (Catalog No. 5087)Tween 20 / Sodium Azide Solution (100X) - (Catalog No. 5037)Mounting Fluid - (Catalog No. 5013)

Disclaimer

For in vitro Diagnostic UseCE Mark

General description

Diagnostics Kit

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

SimulFluor is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage and Stability

When stored at 2-8°C, the SimulFluor^® Respiratory Screen is stable up to the expiration date printed on the kit label. Do not freeze or expose to elevated temperatures. Discard any remaining reagent after the kit expiration date.

Warnings and Precautions
Sodium azide (present in the conjugate, monoclonal antibodies, wash buffer, and mounting fluid) can react with lead or copper plumbing to form potentially explosive metal azides. When disposing of these materials, flush with large volumes of water to prevent azide build-up.
Pooling or diluting conjugates or monoclonal antibodies may cause erroneous results.
Do not allow slides to dry at any time during the staining procedure.
Handle all specimens and materials as if potentially infectious. Decontaminate with 0.05% sodium hypochlorite (a 1:100 dilution of household bleach) prior to disposal.
Do not expose reagents to bright light during storage or incubation.
Avoid contact with Evans blue (present in the SimulFluor™ Respiratory Screen) as it is a potential carcinogen. If skin contact occurs, flush with large volumes of water.
Acetone is extremely flammable and harmful if swallowed or inhaled. Keep away from heat, sparks, or flames. Avoid breathing vapor. Use adequate ventilation.
Do not mouth pipette reagents.
Do not substitute reagents from other manufacturers.
Alteration of protocol provided may cause erroneous results.
When staining multiple samples on a slide, avoid cross contamination between samples.
Mounting Fluid contains a fluorescence enhancer that may be destructive to mucous membranes. Avoid direct skin or mucous membrane contact. If contact occurs, flush with large volumes of water.
If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected with appropriate infection control precautions for novel virulent influenza viruses and sent to state or local health department for testing. Viral culture should not be attempted in these cases unless a Biosafety Level 3 (BSL 3+) facility is available to receive and culture specimens.